摘要
目的:明确肺癌组织hMLH1及hMSH2表达对晚期非小细胞肺癌(non-samll cell lung cancer,NSCLC)含铂化疗疗效及生存的预测价值。方法:采用免疫组织化学的方法对39例福尔马林固定石蜡包埋NSCLC标本进行hMLH1、hMSH2检测,并分析二者与化疗疗效及生存之间的关系。结果:61.5%(24/39)有hMLH1的表达,66.7%(26/39)有hMSH2表达。hMLH1和hMSH2的表达与患者的性别、年龄、肿瘤病理类型、肿瘤分化程度、吸烟史及吸烟指数均无相关性;二者的表达对化疗的反应率(Response Rate,RR)和总生存(Overall Survival,OS)也无预测作用;hMLH1阳性者的至疾病进展时间(Time To Progression,TTP)较hMLH1阴性者明显延长,二者分别为10.9和6.1个月(P<0.05)。hMSH2表达与否对TTP没有影响。结论:hMSH1在肺癌组织的表达情况可能预测晚期NSCLC患者一线化疗的TTP。
Objective： To test the value of hMLH1 and hMSH2 expression in predicting chemotherapy outcome and long-term survival of end stage non-small cell lung cancer.Methods： A total of 39 paraffin-embedded tumor samples from patients with non-small cell lung cancer were used to detect hMLH1 and hMSH2 expression by immunohistochemistry.Relationship between the efficacy/survival after platinum-based chemotherapy and the hMLH1/hMSH2 expression was analyzed,and their prognostic values in time to progression（TTP） and overall survival（OS） were also evaluated.Results： hMLH1 was expressed in 61.5%（24/39） of tumors,and hMSH2 in 66.7%（26/39）.Expression of hMLH1 and hMSH2 did not relate with gender,age,pathologic type,grade of differentiation,smoking history and smoking index;it did not impact on response rate and OS.TTP was statistically longer in hMLH1-positive patients（10.9 months） than that in negative ones（6.1 months,P0.05）.TTP was similar in hMSH2-positive and negative patients.Conclusion： hMLH1 may have a predictive value in TTP of first line chemotherapy for NSCLC.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第17期1566-1570,共5页
Chinese Journal of New Drugs
